Genscript Biotech sees highest filings and grants during August in Q3 2023
Genscript Biotech has been focused on protecting inventions in United States(US) with 9 publications in Q3 2023
The United States(US) Patent Office dominates the patent filings and grants with nearly 26% filings and 60% grants. The United States(US), China(CN), World Intellectual Property Organization(WIPO), and South Korea(KR) patent Office are among the top ten patent offices where Genscript Biotech is filings its patents. Among the top granted patent authorities, Genscript Biotech has 60% of its grants in United States(US), 20% in European Patent Office(EPO), and 0% in China(CN).
Johnson & Johnson could be the strongest competitor for Genscript Biotech
Johnson & Johnson and Pfizer secured the top positions according to recent patent publication data.
Patents related to rare diseases and cell & gene therapy lead Genscript Biotech’s portfolio
Genscript Biotech has the highest number of patents in rare diseases followed by, cell & gene therapy and immuno-oncology. For rare diseases, nearly 47% of patents were filed and 0% of patents were granted in Q3 2023.
Cell therapy related patents lead Genscript Biotech portfolio followed by advanced malignancy, and multiple myeloma (kahler disease)
Genscript Biotech has highest number of patents in cell therapy followed by advanced malignancy, multiple myeloma (kahler disease), non-hodgkin lymphoma and acute lymphocytic leukemia (all, acute lymphoblastic leukemia). For cell therapy, nearly 5% of patents were filed and 0% of patents were granted in Q3 2023.
For comprehensive analysis of Genscript Biotech‘s filings and grants, buy the databook here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Source link
#Genscript #Biotech #sees #highest #filings #grants #August